Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer

AbstractProstate cancer is the most common cancer among men in the USA. Interestingly, recent studies suggest that patients with inflammatory bowel disease (IBD) are at increased risk of developing prostate cancer. Importantly, patients with IBD who develop prostate cancer require thoughtful care when using immunosuppressants to treat the IBD in the setting of malignancy. Further, consideration must be given to the proximity of the prostate to the gastrointestinal tract when treating with radiation where there is concern for the effects of inadvertent exposure of radiation to the diseased bowel. In general, management of immunosuppression after diagnosis of prostate cancer is contingent on the specific immunosuppressive agents, the duration of cancer remission and/or plans for cancer treatment, and the potential risks and benefits of stopping or altering the administration of those agents. Concerns that patients with IBD would have increased risk of disease exacerbation and gastrointestinal toxicity have previously limited the use of radiation. While currently no consensus has been reached regarding the safety of radiation therapy in patients with IBD, recent studies suggest that radiation therapy may be used safely in patients with IBD who develop prostate cancer, especially brachytherapy and intensity-modulated radiation therapy which may have less bowel toxicity compared to conventional methods of external beam radiation therapy. A multidisciplinary team approach including...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research

Related Links:

Abstract In tribute to our friend and colleague Michael Robinson, we review his involvement in the identification, characterization and localization of the metallopeptidase glutamate carboxypeptidase II (GCPII), originally called NAALADase. While Mike was characterizing NAALADase in the brain, the protein was independently identified by other laboratories in human prostate where it was termed prostate specific membrane antigen (PSMA) and in the intestines where it was named Folate Hydrolase 1 (FOLH1). It was almost a decade to establish that NAALADase, PSMA, and FOLH1 are encoded by the same gene. The enzyme has e...
Source: Neurochemical Research - Category: Neuroscience Authors: Tags: Neurochem Res Source Type: research
Publication date: Available online 12 November 2019Source: Progress in NeurobiologyAuthor(s): Joseph H. Neale, Tatsuo YamamotoAbstractN-Acetylaspartylglutamate (NAAG) is the third most prevalent neurotransmitter in the mammalian nervous system, yet its therapeutic potential is only now being fully recognized. Drugs that inhibit the inactivation of NAAG by glutamate carboxypeptidase II (GCPII) increase its extracellular concentration and its activation of its receptor, mGluR3. These drugs warrant attention, as they are effective in animal models of several clinical disorders including stroke, traumatic brain injury and schi...
Source: Progress in Neurobiology - Category: Neuroscience Source Type: research
Prostate Cancer and Prostatic Diseases, Published online: 07 October 2019; doi:10.1038/s41391-019-0177-7The association between inflammatory bowel disease and prostate cancer risk: a meta-analysis
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Source Type: research
Publication date: Available online 23 August 2019Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Mingshi Chen, Caihong Yuan, Tianshu XuSummaryBackgroundIn recent years, some studies showed that inflammatory bowel disease (IBD) might be associated with an increased risk of prostate cancer (PC), whereas some other studies indicated that IBD was not associated with the increased risk of PC. In the present study, we aimed to conduct a systematic review and meta-analysis to evaluate the association of IBD and PC risk.MethodsWeb of Science and PubMed were systematically searched on for link of PC risk a...
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
In conclusion, our data show how oncogenic and tumor-suppressive drivers of cellular senescence act to regulate surveillance processes that can be circumvented to enable SnCs to elude immune recognition but can be reversed by cell surface-targeted interventions to purge the SnCs that persist in vitro and in patients. Since eliminating SnCs can prevent tumor progression, delay the onset of degenerative diseases, and restore fitness; since NKG2D-Ls are not widely expressed in healthy human tissues and NKG2D-L shedding is an evasion mechanism also employed by tumor cells; and since increasing numbers of B cells express NKG2D ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
PET imaging with radiotracers to accurately identify molecules in cancer cells...Read more on AuntMinnie.comRelated Reading: PET tracer may aid diagnosis of inflammatory bowel disease Immuno-PET tracer offers hope for early cancer treatment Novel PET tracer could identify bacterial infections Immuno-PET radiotracers may aid cancer treatment Novel PET tracer aids recurrent prostate cancer patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Publication date: Available online 1 June 2019Source: European UrologyAuthor(s): Zeynep G. Gul, Alberto Martini, Carl A. Olsson
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 28 May 2019Source: European UrologyAuthor(s): Jacob A. Burns, Adam B. Weiner, Shilajit Kundu
Source: European Urology - Category: Urology & Nephrology Source Type: research
Joseph D. Romano1,2,3,4 and Nicholas P. Tatonetti1,2,3,4* 1Department of Biomedical Informatics, Columbia University, New York, NY, United States 2Department of Systems Biology, Columbia University, New York, NY, United States 3Department of Medicine, Columbia University, New York, NY, United States 4Data Science Institute, Columbia University, New York, NY, United States The discovery of new pharmaceutical drugs is one of the preeminent tasks—scientifically, economically, and socially—in biomedical research. Advances in informatics and computational biology have increased productivity at many stag...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In this study, we evaluated the effect of auranofin on the radiosensitivity of intestinal epithelial cells. The treatment with a combination of 1 μM auranofin and 5 Gy ionizing radiation showed clear additive effects on caspase 3 cleavage and apoptotic DNA fragmentation in IEC-6 cells, and auranofin administration significantly aggravated the radiation-induced intestinal injury in mice. Auranofin treatment also resulted in the activation of the unfolded protein response and in the inhibition of thioredoxin reductase, which is a key component of the cellular antioxidant system. Pre-treatment with N-acetyl cysteine, a wel...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | External Beam Therapy | Gastroenterology | Inflammatory Bowel Disease | Intensity-Modulated Radiation Therapy | Prostate Cancer | Radiation Therapy | Study | Toxicology | Urology & Nephrology